Our results from the use of AR inhibitors in different preclinical models indicate that AR inhibitors such as fidarestat could be such a drug that can be used in the amelioration of inflammatory diseases including cardiovascular, sepsis, infection and autoimmune-induced uveitis, allergic asthma, cancer and metastasis, and angiogenesis [73, 108]. The gene discussed is AR; the disease is Sepsis.